sorrento
therapeutics
viralclear
enter
agreement
explore
combination
antibody
plus
antiviral
therapy
sorrento
initiate
testing
selection
agents
combination
viralclear
compound
possible
synergistic
effect
preclinical
model
golden
syrian
hamster
viralclear
contribute
oral
antiviral
merimepodib
impdh
inhibitor
currently
phase
trial
combination
remdesivir
treat
sorrento
initially
make
available
neutralizing
antibody
candidate
testing
westport
globe
newswire
viralclear
pharmaceuticals
nasdaq
bsgm
sorrento
therapeutics
nasdaq
srne
sorrento
announced
companies
exploring
synergistic
potential
small
molecules
antibodies
combination
therapies
general
approaches
considered
likely
succeed
strategies
even
highly
effective
therapies
synergistic
combination
pursued
help
reduce
effective
dose
needed
individual
agent
aim
ensure
maximum
effect
agreement
viralclear
pharmaceuticals
parent
company
biosig
technologies
nasdaq
bsgm
sorrento
therapeutics
allow
testing
merimepodib
neutralizing
antibodies
golden
syrian
hamster
model
study
look
synergy
effective
doses
two
drugs
already
human
clinical
trials
try
specifically
demonstrate
combined
benefits
strengthening
accelerating
viral
clearance
exceed
drug
could
deliver
pending
outcome
studies
results
might
presented
fda
support
initiation
human
clinical
trial
drug
combination
viralclear
pharmaceuticals
merimepodib
biosig
technologies
inc
nasdaq
bsgm
subsidiary
viralclear
pharmaceuticals
viralclear
seeking
develop
novel
pharmaceutical
called
merimepodib
treat
patients
merimepodib
intended
orally
administered
demonstrated
vitro
antiviral
activity
including
strong
activity
cell
cultures
merimepodib
previously
development
treatment
chronic
hepatitis
c
psoriasis
vertex
pharmaceuticals
incorporated
vertex
clinical
trials
phase
phase
subjects
patients
extensive
preclinical
safety
package
completed
manuscript
titled
impdh
inhibitor
merimepodib
provided
combination
adenosine
analogue
remdesivir
reduces
replication
undetectable
levels
vitro
submitted
online
life
sciences
journal
manuscript
authored
natalya
bukreyeva
rachel
sattler
emily
mantlo
john
manning
cheng
huang
slobodan
paessler
utmb
galveston
national
laboratory
jerome
zeldis
viralclear
corresponding
author
article
highlights
data
generated
contract
galveston
national
laboratory
university
texas
medical
branch
sorrento
therapeutics
sorrento
clinical
stage
biopharmaceutical
company
developing
new
therapies
treat
cancers
sorrento
multimodal
multipronged
approach
fighting
cancer
made
possible
extensive
platforms
including
key
assets
fully
human
antibodies
library
clinical
stage
therapies
conjugates
adcs
clinical
stage
oncolytic
virus
sorrento
also
developing
potential
antiviral
therapies
vaccines
coronaviruses
including
diagnostic
test
solutions
including
sorrento
commitment
therapies
patients
also
demonstrated
effort
advance
agonist
pain
management
small
molecule
resiniferatoxin
rtx
lidocaine
topical
system
treatment
neuralgia
rtx
completed
phase
trial
intractable
pain
associated
cancer
phase
trial
osteoarthritis
patients
approved
fda
february
information
visit
statements
press
release
statements
made
presentation
meeting
contain
statements
related
sorrento
therapeutics
safe
harbor
provisions
section
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
statements
regarding
potency
potential
blocking
capabilities
impact
preclinical
testing
safety
efficacy
expectation
commencement
pivotal
trials
predictive
value
animal
model
used
preclinical
studies
human
equivalent
dose
may
required
expected
method
administration
expected
dosage
amount
rate
thereof
potential
applications
potential
low
efficacious
dose
potentially
faster
efficient
manufacturing
speed
availability
potential
lower
cost
strategic
prioritization
ind
submission
sorrento
potential
position
antiviral
industry
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
statements
include
limited
risks
related
sorrento
subsidiaries
affiliates
partners
technologies
prospects
collaborations
partners
including
limited
risks
related
conducting
preclinical
studies
seeking
ind
regulatory
approval
conducting
receiving
results
clinical
trials
clinical
commercial
success
preventing
treating
virus
infections
viability
success
therapeutic
areas
including
coronaviruses
clinical
development
risks
including
risks
progress
timing
cost
results
clinical
trials
product
development
programs
risk
difficulties
delays
obtaining
regulatory
approvals
risks
clinical
study
results
may
meet
endpoints
clinical
study
data
generated
studies
may
support
regulatory
submission
approval
risks
prior
test
study
trial
results
may
replicated
future
studies
trials
risks
manufacturing
supplying
drug
product
risks
related
leveraging
expertise
employees
subsidiaries
affiliates
partners
assist
company
execution
therapeutic
product
candidates
strategies
risks
related
global
impact
risks
described
sorrento
recent
periodic
reports
filed
securities
exchange
commission
including
sorrento
annual
report
form
year
ended
december
subsequent
quarterly
reports
form
filed
securities
exchange
commission
including
risk
factors
set
forth
filings
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
required
law
contact
alexis
nahama
dvm
svp
corporate
development
email
mediarelations
sorrento
logo
registered
trademarks
sorrento
therapeutics
trademarks
sorrento
therapeutics
trademark
owned
scilex
pharmaceuticals
trademarks
property
respective
owners
sorrento
therapeutics
rights
reserved
